CCT7

Across TCGA pan-cancer cohorts, CCT7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCT7 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCT7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCT7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

LUAD, HNSC, and COAD are the cancer types where CCT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.610	0.926	.003	17	view →
HNSC	OS	Median	All	1.000	0.449	.023	10	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	6	view →
CCRCC	OS	Tertile	All	0.720	0.884	.020	3	view →
PDAC	DFS	Median	All	0.430	0.280	.033	2	view →
LSCC	DFS	Quartile	II,III,IV	0.835	0.440	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCT7–LUAD (OS)

Open the LUAD breakdown →